Yirui Pharma Secures Tens of Millions in Series A+ Round; Bonacia Raises Nearly RMB 100 Million in Series B1; Longyao Bio Completes RMB 100 Million Series A Financing

Dec 18, 2023 18:40 CST Updated 18:40

Yirui Pharma

Small Molecule Drug Developer

Longyao Biotechnology

Developer of Tumor Immune Cell Technologies and Products

Yirui Pharma Completes Tens of Millions of Yuan in Series A+ Financing, Accelerating the Development of Small Molecule Innovative Targeted Drugs

News on the 18th, Hangzhou Yirui Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Yirui Pharma") announced the completion ofTaikun FundLed by [Investor Name], with participation from Beijing Tianfeng Capital, Hangzhou Shenghui Investment, and other funds, in a multi-million yuan Series A+ round. The proceeds will be used to accelerate the U.S. Phase II clinical trial of the innovative drug YR-001 for the treatment of autoimmune skin diseases, as well as for the preclinical and early clinical development of other projects within the company.

Yirui PharmaFounded in 2018, it is a company focused on the research and development of small-molecule innovative targeted drugs.BiotechEnterprise, committed to source innovation through scientific project initiation, low cost, high efficiency, and effective risk control strategies. The company focuses on independent research and development, with indications covering autoimmune diseases,Diabetic Complications, and other fields of chronic inflammatory diseases. Differential layouts have been carried out in terms of drug targets, indication selection, drug delivery methods, and treatment populations, striving to provide new first-line medications for the unmet clinical needs of hundreds of millions of patients worldwide.

Due to the overall downturn of the global economy, the investment enthusiasm for the biopharmaceutical industry plummeted after the second half of 2022. Many investment institutions completely withdrew from the biopharmaceutical sector, and the entire new drug development field entered a "rapid freeze" period in terms of financing. The successful completion of this Series A+ round of financing once again demonstrates the market's recognition and trust in Yirui Pharma's R&D team and capabilities. This round of investment will provide strong support for Yirui Pharma's research and clinical trials.

Clinical CRO Bonacia Completes Nearly 100 Million Yuan B1 Round Financing, Accelerating Expansion into North America and Southeast Asia Markets

News on the 18th, Bonacia (Hefei) Pharmaceutical Technology Co., Ltd. ("Bonacia"), a CRO company focused on clinical research, has recently completed a nearly RMB 100 million Series B1 financing. This round of financing was led by Cornerstone Capital, with participation from Jinhe Capital, and Probe Capital served as the financial advisor. The funds will help the company vigorously promote its internationalization and digital intelligence business, further expanding into the North American and Southeast Asian markets.

Bonacia was founded in 2004 as a CRO company specializing in pharmaceutical R&D and clinical research. It is committed to providing comprehensive solutions for clinical research and registration applications for chemical drugs, biologics, and vaccines, while offering full-scale professional medical services for clinical research to pharmaceutical enterprises both in China and internationally. After nearly 20 years of development and accumulation, it has successfully completed over 200 projects across more than 20 therapeutic areas including oncology, autoimmune diseases, metabolism, respiratory, and ophthalmology. The company has established offices in 20 major provinces and cities in China and has developed close collaborations with 80% of clinical trial institutions across the country. It possesses a professional team operating according to international standards (ICH-GCP) and has a complete, standardized, and detailed set of Standard Operating Procedures (SOPs).

Shanghai Longyao Biological Technology Co.,LTD. Completes First Round of Nearly 100 Million RMB Financing

Recently, China Biotech Services announced that its subsidiary, Shanghai Longyao Biological Technology Co., LTD. (hereinafter referred to as "Longyao Bio"), has completed the first round of financing of nearly 100 million RMB, with a pre-investment valuation of approximately 800 million RMB.

This round of financing was led by Yixing Environmental Science Park Industrial Development Equity Investment Partnership (Limited Partnership), with the controlling shareholder, China Biotech Services, continuing to increase its investment. The funds from this round of financing will mainly be used for the phase II clinical trials of the CD20--OX40 CAR-T product and clinical research of other solid tumor pipeline products, as well as the construction of a new GMP cell production laboratory in Yixing. Shanghai Longyao Biological Technology Co., LTD. was established in 2013 and is dedicated to the research and development of tumor immunotherapy cell technologies and products. It is a high-tech enterprise mainly focused on R&D and product development. The company has already laid out multiple tumor immunotherapy cell product pipelines, covering areas such as hematological tumors and solid tumors.

Editor: yc